Search research articles
Contact Us
Filters
Showing results (791-800 of 872) with videos related to
Page
of 88
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
Heiko Becker, Guido Marcucci, Kati Maharry, et al.
ACS Medicinal Chemistry Letters
|
May 19, 2022
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8)
Ratna Kumar Sreekantha, Christopher P Mussari, Dharmpal S Dodd, et al.
ACS Medicinal Chemistry Letters
|
September 18, 2020
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9)
Christopher P Mussari, Dharmpal S Dodd, Ratna Kumar Sreekantha, et al.
Nature Ecology & Evolution
|
March 24, 2020
Why conservation biology can benefit from sensory ecology
Davide M Dominoni, Wouter Halfwerk, Emily Baird, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2014
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases
Qing Shi, Andrew Tebben, Alaric J Dyckman, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 2, 2016
Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors
Rajeev S Bhide, James Neels, Lan-Ying Qin, et al.
Cancer Research
|
April 23, 2009
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival
Jeremy R Graff, Bruce W Konicek, Rebecca L Lynch, et al.
Neuropharmacology
|
January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonist
Jeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.
Haematologica
|
June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Heiko Becker, Kati Maharry, Michael D Radmacher, et al.
Nature
|
February 16, 2016
Stable amorphous georgeite as a precursor to a high-activity catalyst
Simon A Kondrat, Paul J Smith, Peter P Wells, et al.
Page
of 88
Search research articles
Search
Showing results (791-800 of 872) with videos related to
Sort By:
Page
of 88
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
Heiko Becker, Guido Marcucci, Kati Maharry, et al.
ACS Medicinal Chemistry Letters
|
May 19, 2022
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8)
Ratna Kumar Sreekantha, Christopher P Mussari, Dharmpal S Dodd, et al.
ACS Medicinal Chemistry Letters
|
September 18, 2020
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9)
Christopher P Mussari, Dharmpal S Dodd, Ratna Kumar Sreekantha, et al.
Nature Ecology & Evolution
|
March 24, 2020
Why conservation biology can benefit from sensory ecology
Davide M Dominoni, Wouter Halfwerk, Emily Baird, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2014
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases
Qing Shi, Andrew Tebben, Alaric J Dyckman, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 2, 2016
Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors
Rajeev S Bhide, James Neels, Lan-Ying Qin, et al.
Cancer Research
|
April 23, 2009
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival
Jeremy R Graff, Bruce W Konicek, Rebecca L Lynch, et al.
Neuropharmacology
|
January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonist
Jeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.
Haematologica
|
June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Heiko Becker, Kati Maharry, Michael D Radmacher, et al.
Nature
|
February 16, 2016
Stable amorphous georgeite as a precursor to a high-activity catalyst
Simon A Kondrat, Paul J Smith, Peter P Wells, et al.
Page
of 88